



ASX release

21 January 2009

H1 sales surge 76% AtCor upgrades guidance for FY2009

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced unaudited H1 FY2009 sales of \$5.4 million, a 76% increase over H1 FY2008 and a record for the company. On a constant currency basis, sales increased 64% over the previous corresponding period (pcp).

Sales were up 125% in the United States in H1 FY2009 compared to H1 FY2008, reflecting increased demand for central blood pressure measurement using SphygmoCor in pharmaceutical clinical trials. Coming off a strong prior year performance, European sales rose 26% on the pcp, and Asian sales grew by 11%.

AtCor chief executive officer Duncan Ross said, "The strong sales momentum achieved in the past two years has continued, and we maintain a healthy sales pipeline. Despite seeing some impact from the macro economic environment we have upgraded AtCor's full year sales guidance to an increase of 55% for FY2009 over FY2008, up from the 45% increase we anticipated in November. We expect full year sales of at least \$10.0 million."

The company today lodged its quarterly cash flow report with ASX. This showed a \$1.2 million reduction in operating cash outflows for H1 FY2009 compared to the pcp (H1 FY2009: \$1.159 million vs. H1: FY2008: \$2.377 million). Cash at 31 December 2008 was \$2.924 million. With increasing sales, strong trade receivables and continued reduction in cash outflow expected, AtCor does not anticipate a need to raise funds for operating purposes in the foreseeable future.

AtCor's half-year results will be announced on 19 February 2009.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,800 SphygmoCor[®] systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au